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EVIDENCE FOR THE EXISTENCE OF AT LEAST TWO 
DIFFERENT BINDING SITES FOR SHT-REUPTAKE 
INHIBITORS WITHIN THE SHT-REUPTAKE SYSTEM FROM 
HUMAN PLATELETS 
ERIK A. L. BIESSEN,*?~ JAN A. NORDER,* ALAN S. HORN* and GEORGE T. 
ROBILLARD~ 
* Department of Medicinal Chemistry, Subfaculty of Pharmacy, 7Department of Physical 
Chemistry, University of Groningen, Groningen, The Netherlands 
(Received 25 Junta 1988; accepted 3 May 1988) 
Abstract--Chemical modification procedures have been used to study the interaction of tricyclic and 
non-tricyclic SHT-reuptake inhibitors with the [3H]imipramine binding site (IBS). N-Ethoxycarbonyl- 
2ethoxy-1,2-dihydroquinoline (EEDQ) induced a pronounced loss in [‘Hlimipramine binding due to a 
reduction in B,,. Preincubation with reuptake inhibitors and subsequent inactivation by EEDQ revealed 
that imipramine and 5HT prevented the EEDQ-induced inhibition, but citalopram and fluoxetine did 
not. Tbiol modification studies demonstrated that reduction by dithiothreitol (D’I’T) enhanced the 
binding of [‘H]imipramine by increasing the B,. The thioselective reagents l,l-diaxobis- (N,N- 
dimethylformamide) (diamide), phenyl-amineoxide (PAO) and N-ethylmaleimide (NEM) attenuated 
the binding capacity by lowering the B,,. PAO, a reversible thiol reagent, prevented NEM alkylation 
indicating that dithiols are involved in the NEM-induced inactivation. Binding of tricyclics or non- 
tricyclics prior to PA0 inactivation revealed that tricyclics provide complete protection against hiol 
modification, while the non-tricyclics do not. The results upport the hypothesis that the SHT-reuptake 
system of human platelets possesses at least two ~stinguishable binding sites. 
The 5HT reuptake system appears to be an aggregate 
of closely interacting subunits. In spite of many bind- 
ing studies (for a review see [l]) considerable uncer- 
tainty remains concerning the nature and number of 
inhibitor binding sites. Radiation inactivation data 
showed that the functional molecular size of the 
[3H]imipramine binding site (IBS)§ differed sig- 
nificantly from that of [ 3H]paroxetine, a non-tricyclic 
compound [2]. This suggests separate sites on dif- 
ferent subunits. Reuptake inhibitors have been div- 
ided into at least two distinct groups on the basis of 
the cooperativity of [ 3H]imipramine binding [3-51. 
Thermodynamic studies were compatible with this 
finding; non-tricyclics induced a more drastic con- 
fo~ational change than tricyclics [5]. 
Chemical modification studies can provide an 
additional tool for investigating the characteristics of 
a site at a molecular level in a non-purified system. 
This technique involves selective alterations of 
$ Send correspondence to: E. A. L. Biessen, Dept. 
Medic. Chem., Subfaculty of Pharmacy, University of 
Groningen, Ant. Deusinglaan 2,9713 AW Groningen, The 
Netherlands. 
fj Abbreviations used: diamide, 1-I-azobis(N,N- 
dimethyl formamide); DTE, dithioerythreitol; DTNB, 
dithio (bis&nitrobenzoate)); DTT, dithiothreitol; EEDQ, 
N-ethoxycarbonyl-3-ethoxyl-1,2 dihydroquinoline; IBS, 
imipramine binding site; NEM, N-ethylmaleimide; PEI, 
~lyethylene imine; PMSF, phenylmethyl sulfonyl~uo~de; 
S-HT, S-hydroxy tryptamine. 
amino-acids within or close to the binding site and, 
in addition, protection against mo~ficatio~ by prior 
binding of substrates or drugs. Selective reagents like 
dithiothreitol (DTT), 5,5’-dithio bis(Znitrobenzo- 
ate) (DTNB), N-ethylmaleimide (NEM) and mer- 
cury compounds like p-chloromercuribenzoate 
(PCMB) have been used extensively to probe the 
potential role of sulfhydryl groups in the process of 
drug binding to several receptor systems, including 
the 5-HT reuptake -system [7,8]. Peterson and 
Bartfai [9] proposed that the latter might contain 
Cd*‘-sensitive groups, probably vicinal dithiols. 
Davis [lo] also investigated the involvement of the 
cysteines on the structure of the imipramine binding 
site (IBS) and the potency of reuptake inhibitors to 
protect against disuffide reduction by dithio- 
erythreitol. Biassoni and Vaccari [ll] reported that 
thiol-reducing reagents seemed to increase both the 
[3H]imipramine binding and the uptake of %-IT. 
Furthermore, modification of the cysteine groups 
with NEM, PCMB and DTNB decreased the binding 
of [3H]imipra~ne. 
A chemical modification approach frequently 
applied in in-uivo receptor research, involves cross- 
linking with N-ethoxycarbonyl-2-ethoxy-1,2-di- 
hydroquinoline (EEDQ). This reagent links car- 
bony1 moieties to vi&al amino groups. The chemical 
modification studies reported below strongly favour 
the involvement of dithiols in the process of drug 
binding, and the existence of at least two distinct 
3959 
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binding sites: one for the so-called tricyclics, the 
other for non-tricyclic compounds. Modification 
experiments with EEDQ support the assumption 
of different binding sites within the 5HT-reuptake 
system. 
MATERIALS AND METHODS 
Platelet membrane preparation 
The platelet membranes were prepared according 
to a modified version of the method of Mellerup et 
al. f12). Outdated human platelet-rich concentrates 
(obtained from the Blood Bank, Groningen) were 
centrifuged (6OOg, 10min) to remove the erythro- 
cytes and lymphocytes. From this point on the tissue 
was kept at 4” throughout the preparation. The 
supernatant was centrifuged (5000 g, 10 min); the 
pellet was washed with buffer A, 150mM NaCI, 
50mM Tris/HCl, 20 mM EDTA, 1 mM DTT, 
0.1 mM phenylmethyl sulfonylfluoride (a protease 
inhibitor), H = 7.5, and resuspended in buffer B, 
5 mM Tris P HCl, 5 mM EDTA, 1 mM D’IT, 0.1 mM 
PMSF, pH = 7.5. The platelets were lysed by hom- 
ogenization of the suspension in hypotonic buffer 
with an Ultra Turrax (3 X 10 set; 2000 rpm). Then 
the suspension was centrifuged at 50,000 
f 
for 
10 min, resuspended in buffer C (70 mM Tris HCl, 
l.OmM DTI, 0.1 mM PMSF, pH = 7.5) and 
recentrifuged. Finally, the platelet membranes were 
resuspended in incubation buffer, 120 mM NaCI, 
50 mM Tris/HCl, 5 mM KCl, 1 mM EDTA, 2 mM 
MgC&, 1 mM DTT, 0.1 mM PMSF, pH = 7.5 and 
stored in liquid nitrogen at a protein concentration 
of 15-20 mg/ml. 
[ 3Hjimipramine binding assay 
Radioligand-binding assays were performed in 
borosilicate culture tubes (12 X 75 mm; Kimble, 
U.S.A.). The specific binding of ~3H]imipramine 
(spec. act. :45-51 Ci/mmol) on platelet membranes 
was determined as the difference of binding in the 
absence and presence of excess citalopram (10 PM), 
a highly selective 5-HT reuptake inhibitor, by a 
filtration procedure over Whatman GF/F glass fibre 
filters. In short, 300 ~1 aliquots containing approxi- 
mately 1 mg protein/ml and a fixed concentration of 
[3H]imipramine were incubated for 60 min at 4”. In 
the case of a saturation experiment, the 
[3H]imipramine concentration ranged from 0.3 to 
20nM. Displacement studies were performed at a 
fixed concentration of [3H]imipramine, in the pres- 
ence of unlabelled reuptake inhibitor, ranging in 
concentration from 0.1 nM to 10 PM. The incubation 
was terminated by rapid filtration on a Millipore 
manifold under vacuum, using Whatman GF/F 
filters, preincubated in buffer containing 0.3% poly- 
ethyleneimine to reduce non-specific binding. 
The filters were washed with 3 X 3 ml ice-cold 
buffer. Radioactivity was measured after overnight 
incubation in 4 ml Packard Emulsifier Scintillator 
299 in a Beckman scintillation counter with a count- 
ing efficiency of about 45%. 
Tkiol modification studies 
Inactivation with thiol reagents. Receptor-mod- 
ifying reagents were added to the platelet membrane 
suspension after complete reduction of the receptor 
suspension with 25 mM DTT for 30min at 20” and 
three wash-steps with incubation buffer to reduce 
the DTT concentration to 1 mM. Thiol modification 
was achieved by reaction for 30 min at 20” with 7 mM 
NEM, 1 mM phenylarsine oxide (PAO) or 5 mM 
diamide. NEM and PA0 were added from stock 
solutions containing about 1 M and 100 mM reagent 
in ethanol, respectively. The final concentration of 
ethanol never exceeded 1%. The NEM-induced 
~kylation was stopped by adding 25 mM DTT to the 
membrane suspension. The reversibility of the PAO- 
and diamide-induced oxidation was tested by incu- 
bation with 25 mM DTT for 30 min at 4” after the 
inactivation procedure. The binding of [3H]imi- 
pramine to the chemically modified membrane- 
bound IBS was determined (in quadruplicate) at a 
fixed [3H]imipramine concentration. 
Protection against chemical modification by thiol 
reagents. The membrane suspension was pretreated 
with 25 mM DTT at 20“ for 15 min, then washed to 
reduce the DTI concentration to 1 mM and sub- 
sequently preincubated for 30 min at 0” with excess 
reuptake inhibitors at the following concentrations: 
10 @vI for citalopram, fluoxetine, femoxetine, imi- 
pramine, clomipra~ne, cyanopr~ine and amitryp- 
tiline and 100 PM for zimelidine, nor-zimelidine and 
5HT. Then the suspensions were exposed to 1 mM 
PA0 for 30 min at 20” as described above. After the 
incubation procedure, the membrane suspension was 
rinsed at least three times with incubation buffer by 
centrifugation at 50,000 g for 10 min to remove the 
reuptake inhibitor. To test the completeness of the 
washing-procedure, a so-called washing control was 
included (preincubation with reuptake inhibitors fol- 
lowed by the above mentioned wash step). Finally 
the [3H]imipramine-binding was determined at 5- 
7 nM, in quadruphcate. 
Inactivation with EEDQ 
The optimal inactivation conditions were deter- 
mined by examining the effects of incubation time 
at 20”, pH = 7.0 and 0.4 mM EEDQ, the effects of 
EEDQ-concentration at 20”, pH = 7.0 for 30min 
and the effects of incubation pH at 20”, 0.4mM 
EEDQ for 30min. The inactivation was started by 
adding EEDQ, dissolved in ethanol, to the receptor 
suspension in SO mM sodium phosphate, 70 mM 
NaCl, 5 mM KCl, 2 mM MgC12, 1 mM EDTA. The 
inactivation was stopped with 10 mM DTI, putting 
the suspension on ice. Then the suspension was 
rinsed once with incubation buffer to reduce the 
EEDQ concentration. The ~3H]imipramine-bin~ng 
was determined at fixed [ Hlimipramine concen- 
tration (5-7 nM). Protection against modification 
of the IBS with reuptake inhibitors was performed 
as follows. The membrane suspension, in the sodium 
phosphate buffer, was preincubated with excess 
reuptake inhibitor (1 PM imipramine, fluoxetine, 
citalopram or 100 PM 5HT) for 30 min at 4”. Then 
the suspension was treated with 0.4mM EEDQ at 
20” and pH = 6.5 for 30 min. The inactivation was 
terminated with addition of 10 mM DTI putting the 
suspension on ice and the samples were washed 
three times with incubation buffer to remove excess 
reuptake inhibitor. Finally, a [3H]imipramine satu- 
ration curve was determined (in triplicate). 
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Data calculation and statistical analysis 
The saturation curve data were subjected to 
Hanes-Woolf analysis [13] or to a non-linear fitting 
program (minimizing the sum of squares via the 
Simplex-iteration procedure). The pseudo-Hill coef- 
ficients were calculated from displacement curves 
using a computerised non-linear regression 
procedure. Data were evaluated statistically using 
the Student’s t-test for paired values. 
Materials 
All chemicals were reagent grade. The reuptake 
inhibitors were generous gifts from their respective 
firms: imipramine and clomipramine from Ciba- 
Geigy Lab (Basel, Switzerland), cyanopramine and 
amitryptiline from Roche (Neuilly-sur-Seine, 
France), fluoxetine from Lilly Co. (Indianapolis, 
IN), citalopram from Lundbeck (Copenhagen, Den- 
mark), norzimelidine and zimelidine from Astra 
(Sweden) and finally femoxetin from Ferrosan 
(Denmark). [3H]imipramine was purchased from 
New England Nuclear (Boston, MA; 45.3 Ci/mmol). 
Outdated platelet-rich plasma was kindly supplied 
by the Bloodbank, Groningen, The Netherlands. 
RESULTS 
The binding of radiolabelled ligand has been moni- 
tored in the presence of unlabelled ligand, varying 
in concentration from 0.1 nM to 10 ,uM. From these 
studies, the apparent inhibition constant, Ki, and the 
pseudo Hill coefficient could be evaluated. These 
displacement studies were done to determine the 
pharmacological profile of the SHT-reuptake system. 
Analysis of the results revealed that tricyclics have a 
pseudo-Hill coefficient of one, suggesting normal 
competitive displacement, whereas the non-tricyclics 
tested in these experiments possessed a pseudo-Hill 
coefficient significantly smaller than 1, indicative of 
negative cooperativity (Table 1; P < 0.01). These 
intriguing data prompted us to investigate the inter- 
action of tricyclics and non-tricyclics with the 5HT- 
reuptake receptor more thoroughly. 
EzX$induced inactivation of 13H] imipramine 
. . 
The kinetics of EEDQ-induced crosslinking are 
displayed in Fig. 1. The control sample (without 
EEDQ) did not change significantly during the 
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Fig. 1. Effect of the incubation time with EEDQ on 
13H]imipramine binding. Incubations were done at 0.1 mM 
EEDQ (El), 0.8mM EEDQ (A) and in the absence of 
EEDQ (0) at 20”, pH = 7.0. Binding is shown as the % of 
specific binding (mean 2 SEM of quadruplicate measure- 
ment) relative to a non-exposed control sample. 
exhibit an inactivation of binding capacity. The inac- 
tivation levelled off at 40%. This was most likely a 
consequence of limiting EEDQ concentrations. The 
inactivation rate obeyed simple first order kinetics 
with half-times of 6 min and 30 min at EEDQ con- 
centrations of 0.8 and 0.1 mM, respectively. A strong 
pH dependence was observed. No inactivation 
occurred at high pH but a marked increase in inac- 
tivation was observed with decreasing pH (Fig. 2). 
Consequently, a pH of 6.5 was selected for inac- 
tivation and protection studies. 
The potency of some reuptake blockers to protect 
against EEDQ-induced crosslinking was determined 
as follows, The membrane suspension was pre- 
incubated with 1 PM inhibitor (100 PM in the case of 
5HT on account of its low affinity) prior to EEDQ- 
induced inactivation. After treatment of the mem- 
brane suspension with EEDQ, as described in 
Methods, the modification was terminated by 
addition of DTT. The membrane suspension was 
rinsed thoroughly to remove the drug. Then satu- 
ration curves of the various suspensions were 
determined. Evaluation of the saturation curve data 
Table 1. Pseudo Hill-coefficients of several SHT-reuptake inhibitors determined from 
dispIacement of [ 3H]imipramine 
Compound Hill-coefficient Compound Hill-coefficient 
Imipramine 0.99 ” 0.09 (4) Fluoxetine 0.73 rt 0.21 (2) 
Clomipramine 1.15 + 0.14 (3) Citalopram 0.60 i; 0.03 (2) 
Cyanopramine 0.92 2 0.16 (2) Femoxetine 0.42 t 0.08 (1) 
Amit~tiline 1.28 2 0.21 (1) ORG 6582 0.73 +- 0.20 (t) 
5HT 0.78 r 0.13 (1) Nor-zimel. 0.64 rf: 0.16 (1) 
The data were evaluated using a computerised non-linear regression procedure 
(Graph-Pad). Hill coefficients are given as mean rt SEM (in case of a single 
experiment ? SD). In parentheses the number of experiments. 
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Fig. 2. Influence of the incubation pH on the inactivation 
of [3H]imipramine binding by EEDQ. Inactivation was 
carried out with 0.4 mM EEDQ at 20” for 30 min. Binding 
is shown as the % of specific binding relative to a non- 
exposed control sample. Mean of 2 experiments. 
revealed that EEDQ inactivation left the Kd 
unchanged (Kd = 3.07 k 0.27 nM) but lowered the 
B mm significantly (Table 2). This reduction in B,,, 
was quite reproducible. Preincubation of the recep- 
tor with imipramine and 5HT gave partial and com- 
plete protection, respectively, against EEDQ 
inactivation, whereas fluoxetine and citalopram did 
not protect at all. 
Modification of cysteine by thiol reagents 
Preliminary experiments indicated that the redox 
state of the reuptake receptor varied from one mem- 
brane preparation to another and manifested itself 
in an altered B,,, value. Consequently the influence 
of oxidation and reduction on B,,, was investigated. 
As previously reported by Biassoni and Vaccari [ 1 l] 
and Davis [lo], pretreatment with DTT had a posi- 
tive effect on the binding by enhancing the B,, by 
about 35% (P < 0.001; Table 3a). Incubation time 
and DTT concentration-dependent studies showed 
that maximum stimulation could be achieved by a 







Kd (in nM) B,,, (in % of control) 
- - 3.4 2 0.4 look13 
1.0 PM imipramine - 3.7 * 0.5 97 2 4 
- + 2.8 f 0.2* 47 2 5t 
1 .O FM imipramine + 2.9 2 0.4 69 -c 2’ 
100 PM 5HT + 3.7 2 1.3 110 * 12 
1.0 PM citalopram + 2.7 ? 0.6 33 ? 141 
1.0 PM fluoxetine + 2.2 2 0.7 23 2 2t 
The receptor suspensions were preincubated with excess reuptake inhibitor (1 PM 
imipramine, fluoxetine, citalopram and 100 PM 5HT) prior to inactivation at pH 6.5 and then 
reacted with 0.4 mM EEDQ, pH = 6.5 at 20” for 30 min. After termination of the modification 
with DTT (to a final cont. of 10 mM), the suspensions were washed extensively by a three- 
fold centrifuge step to remove the reuptake inhibitor, equilibrating the suspensions for 30 min 
between these wash-steps. Binding parameters from saturation curve data were evaluated via 
Hanes-Woolf analysis (significance: * P < 0.01; t P < 0.005 relative to control). 
Table 3. Binding parameters from saturation curve data evaluated via non- 
linear regression 
(A) Effect of reduction of the membrane suspension with 25 mM DlT (15 min 




Kd (in nM) B,,, (in fmol/mg) 
DTT-treated 
Non-treated 
2.8 t 0.5 670 -c 7%* 
2.3 2 0.4 490 2 1% 
(B) Effect of thiol modification by NEM (7 mM, 30 min, 20”), PA0 (1 mM, 
30min. 20”) and diamide (5 mM, 30min, 20”) after reduction of the 
membrane suspension with 25 mM DlT for 15 min at 20” (t P < 0.0001 
relative to the control value) 
Sample 
Binding parameter 
K,, (in nM) &., (in pmol/mg) 
Control 1.7 2 0.5 453 ? 6% 
PA0 1.5 * 0.5 240 _’ 2%t 
NEM 2.1 -r- 0.6 227 ? 5%t 
Diamide 1.4 + 0.4 187 ? l%t 
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Fig. 3. Effects of DTT on [3H]imipramine binding, The 
membrane suspension was first reduced with 25 mM DTT 
for 15 min at 20” then washed to remove the DTT. Specific 
[3H]imipramine binding (in % of control value at t = 0 min) 
as a function of incubation time at 20” in the absence 
(0) or in the presence of D’IT (1 mM: q ; 2.5 mM: A). 
Mean ? SEM of measurement in quadruplicate. 
30 min incubation with 10 mM DTT at 20” (data not 
shown). As a result of these experiments a standard 
pretreatment protocol was selected involving pre- 
incubation with 25 mM DTI’ for 15 min prior to 
modification. Figure 3 shows that this fully reduced 
state of the IBS was not stable in the absence of 
D’IT. The binding diminished to about 40% within 
2 hr at 20” by reoxidation, despite the presence of 
EDTA. Oxidation was considerably slower in the 
presence of 1 mM DTT. In view of the m~imum 
incubation time at 20”, 1 mM D’IT was satisfactory 
to keep the redox state relatively constant. 
The kinetics of modification with NEM (7 mM), 
diamide (5 mM) and PA0 (1 mM) are described 
in Fig. 4. The control did not change during the 
60 
10 20 30 40 50 60 
- t (mini 
Fig. 4. Kinetics of inactivation of [3H]imipramine binding 
by NEM (U), PA0 (V) and diamide (A). After reduction 
of the platelet membranes with 25 mM DTT for 15 min at 
2W, the DlT concentration was reduced to 1 mM by a wash 
step and the membrane suspension was exposed to 7 mM 
NEM, 1 mM PA0 or 5 mM diamide or Hz0 (0) at 20”. 
Aliquots were taken at various times and [3H]imipramine 
binding was determined. The specific binding is plotted on 
the vertical axis as the mean + SEM, of a quadruplicate 
determination. The data are plotted as the % of the control 
value at t = 0 min. 
1 2 3 4 5 6 
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OTT-reduction + - + - + + + 
Fig. 5. Reversibility of inhibition by PA0 or diamide and 
protection against NEM-induced inhibition of [3H]imi- 
pramine binding. Membranes were exposed to a protector, 
1 mM PA0 or 5 mM diamide, an alkylator, 7 mM NEM, 
and a reductant, 25 mM DTT or some combination of these 
reagents in the order given at the bottom of the figure. The 
exposure times were 30 min for PAO, diamide, NEM and 
for DTT. The specific 13H]imipramine binding is plotted 
on the vertical axis as the average.? SEM, of the number 
of experiments given in the parentheses, each of which was 
carried out in quadruplicate. The data are plotted as the % 
of the non-exposed control. Significance: ** P < 0.0001; 
* P < 0.01 vs control. 
incubation period. NEM, diamide and PA0 induced 
a pronounced loss of [3H]imipramine binding with a 
t& of 22 min, 10 min and 15 min, respectively. The 
NEM alkylation rate is in agreement with the results 
obtained by Davis [lo]. Saturation curves were 
measured to determine whether the modification 
influenced only the B,, and, consequently, whether 
it was permissible to determine the binding at a 
fixed [3H]imipramine concentration. These data are 
presented in Table 3b. Only the B,,, was affected 
by NEM, PA0 and diamide; the reduction in B,,, 
achieved in this experiment (~50%) was less than 
the value obtained in the experiments described in 
Fig. 4 (It25% after 30min). Since the membrane 
suspension in the saturation-curve experiment con- 
tains about 3 times as much protein (15 mg/ml) dur- 
ing the inactivation with PA0 as in the experiments 
described ‘in Figs 4-6, the observed discrepancy 
might be a consequence of slightly limiting PA0 
concentration. Nonetheless, the affinity remained 
virtually unaltered. The reversibility of PA0 and 
diamide inactivation and the ability of PA0 to pro- 
tect against alkylation by NEM are shown in Fig. 5. 
After gross reduction of the IBS with 25 mM DIT, 
the washed membrane suspension containing 1 mM 
DTI was exposed for 30 min at 20” to 1 mM PA0 
or 5 mM diamide. The mixture was then put on ice. 
Protection against NEM atkylation was tested by 
subsequent treatment of the suspension with 7 mM 
NEM for 30 min at 20”, followed by a reduction step 
with 10 mM DTT. Reversibility of the oxidation was 
determined by reduction of the PA0 and diamide 
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Fig. 6. Protection against PA0 induced thiol modification by various reuptake inhibitors. Non-tricyclic 
inhibitors were: citalopram, 10uM; fluoxetine 10uM: femoxetine 1OuM: zimelidine 1OOuM: nor- 
zimelidine 100 pM and tricyclic ‘reuptake inhibitors were: imipramine ‘10 iM; cyanopramiie lb PM; 
clomipramine 10 PM; amitryptiline 10 PM and finally the endogenous drug 5HT, 100 PM. After reduction 
of the membrane suspension with 25 mM DTT (15 min, 20”) the samples were preincubated for 1 hr (4”) 
with reuptake inhibitors, followed by thiol modification with PA0 (1 mM, 30min, 20”). After the 
modification the samples were washed three times to remove the reuptake inhibitor and [ 3H]imipramine 
binding was measured as stated in Methods. No DTT was present during the binding measurements. 
The specific [‘Hlimipramine binding as % of non-exposed, non-preincubated control is plotted on the 
vertical axis. The value is the mean -+ SEM, of the number of experiments given in parentheses. Each 
experiment was run in quadruplicate. Significance *** P < 0.001 vs control, ** P < 0.005, * P < 0.01. 
000 P < 0.001 vs PAO-exposed sample, 00 P < 0.005, 0 P < 0.01. A control of the wash-step was 
included. 
treated samples with excess DTT. Diamide, PAO, 
and NEM inactivate the X-IT-reuptake system to 
about the same extent. The diamide and PA0 
induced inhibition was reversible: the [3H]imi- 
pramine binding returned to 75% of its original 
value. The fact that reversible reaction with PA0 
protected against NEM induced alkylation indicates 
that NEM also reacted with the same dithiol. 
The main point of interest was to test whether or 
not the tricyclic reuptake inhibitors interact with 
the same binding site as do non-tricyclics. Figure 6 
examines the ability of tricyclic and non-tricyclic 
compounds to protect against inactivation by PAO. 
PA0 treatment resulted in a 90% decrease of 
[3H]irnipramine binding. This inactivation was pre- 
vented by preincubation with tricyclics (P < 0.0001). 
As expected from the results of EEDQ inhibition 
studies, even though nontricyclics are able to displace 
imipramine from the IBS, they do not protect against 
PA0 modification. The observed inactivation after 
preincubation with non-tricyclics was not due to 
incomplete washing, since the washing control and 
the untreated control both showed the same high 
value. The only discrepancy with the EEDQ pro- 
tection study lies in the paradoxical effect of 5HT. It 
was not capable of protecting against thiol activation. 
This was not due to oxidation of SHT; however, 
we have monitored oxidation of SHT during the 
incubation time (30 min at 20”) by following the UV 
spectrum of 5HT under the experimental conditions 
and found no significant change was observed in the 
UV spectrum (265-320 nm) of 5HT for at least 1 hr 
(data not shown). 
DISCUSSION 
EEDQ-induced receptor inactivation 
EEDQ has been one of the inhibitors most fre- 
quently applied, in vivo, in order to quantify de 
novo receptor synthesis [14,15] or to investigate the 
potency of drugs to protect against inactivation of 
their respective receptor systems [16]. However, it 
is not widely used in in vitro research, despite the 
obvious advantages for comparison with in vivo 
studies. We have examined the efficacy of two cat- 
egories of reuptake inhibitors and 5HT to protect 
against receptor inactivation by EEDQ in order to 
clarify the possible existence of multiple binding 
sites within the reuptake system. Analysis of Hanes- 
Woolf isotherms revealed that the B,,, decreased 
53% upon EEDQ modification. The Kd was left 
essentially unchanged. 
Reuptake inhibitors can be divided into two 
classes, based on their efficiency to protect against 
EEDQ inactivation. 5HT and imipramine protect 
against EEDQ-induced inactivation, whereas the 
non-tricyclics do not protect. In fact, the nontricyclics 
tend to enhance the EEDQ-induced inactivation. 
From these results it is difficult to decide if the 
protection of imipramine and 5HT against modi- 
fication by EEDQ implies a direct blockade of the 
actual binding site or a binding induced con- 
formational change, which attenuates the accessi- 
bility of amino/carbonyl groups involved in the 
inactivation. 
Chemical modification of cysteines 
Cysteines have been documented in many dif- 
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ferent receptor systems including the adrenergic [7], 
dopaminergic [8] and serotonergic systems [+ 
11,171. Biassoni reported that both [ 3H]imipramine 
binding and 5-[3H]T reuptake was stimulated by 
reduction of what were thought to be disulfides [ 111. 
In agreement, alkylation or oxidation inhibited both 
processes. From these studies he proposed that the 
DTT-induced increase of the drug binding involved 
the low- rather than the high-affinity state of the 
[ 3H]imipramine binding protein. Our thiol modi- 
fication experiments indicate that DTT indeed has a 
stimulating effect on the binding of imipramine by 
enhancing the B,,, 35% presumably by a decrease 
of the fraction of oxidized IBS. The stimulatory 
effect of DTT appeared to be dependent on the 
relevant tissue batch. This might be a consequence 
of minor differences during tissue preparation. Spon- 
taneous oxidation appeared to lead to a 60% 
decrease in binding, whereas chemical oxidation with 
diamide resulted in a 90% decrease of binding 
capacity. This difference is most likely due to the 
redox potential of the incubation mixture. No effort 
was made, in the spontaneous oxidation experiment, 
to saturate the reaction mixture with OZ. The dia- 
mide- and PAO-induced inhibition was reversible 
for 75-80%. Clearly, vicinal dithiols are involved in 
the thiol modification, which results in a reduction 
of [3H]imipramine binding. 
The rather slow NEM modification as observed in 
our laboratory and by Biassoni and Vaccari [ll] and 
Davis [lo] suggests that NEM might inactivate by 
alkylating an inert or hidden thiol group or by react- 
ing non-specifically [18]. In view of the data pre- 
sented above, we can exclude the latter. Either the 
thiols are chemically inert or not readily accessible. 
The observed loss in [3H]-imipramine binding 
activity after thiol modification could be explained 
as an alteration in tertiary structure or as a steric 
hindrance of the binding or it could implicate the 
thiol directly in the process of drug binding itself. 
Davis [lo] reported that blockade of the IBS with 
the non-tricyclic reuptake inhibitor fluoxetine pre- 
vented the DTE-induced increase in binding 
capacity. The results presented in this study are not 
compatible with this feature; non-tricyclics are not 
capable of providing any protection against thiol- 
modification. By contrast, tricyclics protect the IBS 
against both EEDQ- and PAO-induced inactivation. 
The Hill coefficients calculated from our dis- 
placement studies also suggested another type of 
inhibition of [3H]imipramine for non-tricyclics rela- 
tive to tricyclics. The Hill coefficients, obtained by 
Sette etal. [4] and Mellerup et al. [12] were essentially 
the same. In agreement with our conclusions, Reith 
[6] has reported that the non-tricyclics induce a more 
drastic conformational change than the tricyclics, 
possibly from a different type of interaction with the 
protein. Other studies support this finding [3,4,6]. 
Wennogle [19] concluded that one group of dis- 
placers accelerated, whereas a second group attenu- 
ated the dissociation rate of [3H]imipramine. 
On the grounds of the data provided by this study 
and by others, one could propose that binding of 
non-tricyclics involves a binding site, which is closely 
associated with but not identical to the IBS. The 
regulatory IBS, part of the presynaptic complex, 
modulates 5HT reuptake. The nature of the coupling 
of the IBS and SHT-reuptake system remains to be 
clarified. 5HT appears to provide protection against 
EEDQ-induced crosslinking but not against thiol 
modification. It is rather unlikely that its protective 
potency is caused by direct reaction with EEDQ, 
since the EEDQ concentration exceeds by far that 
of serotonin. Thiol modification might affect another 
part of the IBS, possibly the actual recognition site, 
while EEDQ might induce a drastic structural 
change. EEDQ-induced inactivation may be pre- 
vented by conformational changes induced by the 
binding of 5HT or imipramine. By contrast, binding 
of 5HT might leave the thiol groups, essential 
for imipramine binding, still accessible for thiol- 
modifying reagents. 
Further studies on the purified 5HT reuptake sys- 
tem will be necessary to provide a decisive answer 
about the actual mechanism of 5HT reuptake and its 
modulation. 
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